Sarcoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

  NCT03116529· University of Maryland, Baltimore· Updated 5 Nov 2026

  “Limited Accrual”Registry text, quoted unchanged. Source

• Terminated

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Updated 5 Nov 2026

  “\< 75 % participation”Registry text, quoted unchanged. Source

• Suspended

  A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

  NCT05691478· National Cancer Institute (NCI)· Updated 27 Oct 2026

  “Other - Extend the observation period for current patients”Registry text, quoted unchanged. Source

• Withdrawn

  Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

  NCT06712433· Adam Olson· Updated 26 Oct 2026

  “Per the PI, this study is not proceeding due to funding and insufficient support.”Registry text, quoted unchanged. Source

• Terminated

  Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

  NCT06566092· Iovance Biotherapeutics, Inc.· Updated 16 Oct 2026

  “After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.”Registry text, quoted unchanged. Source

• Terminated

  Digital Art Therapy for Young Cancer Survivors

  NCT06789666· UNC Lineberger Comprehensive Cancer Center· Updated 15 Oct 2026

  “Funding unavailable”Registry text, quoted unchanged. Source

• Suspended

  Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

  NCT07052383· Tcelltech Inc.· Updated 14 Oct 2026

  “Data update in progress.”Registry text, quoted unchanged. Source

• Terminated

  Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

  NCT06820957· Children's Oncology Group· Updated 5 Oct 2026

  “Drug supply issues”Registry text, quoted unchanged. Source

• Suspended

  Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

  NCT05264974· University of Florida· Updated 17 Sept 2026

  “seeking additional funding”Registry text, quoted unchanged. Source

• Withdrawn

  CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

  NCT07297160· Baylor College of Medicine· Updated 16 Sept 2026

  “The study was revised into two separate protocols to separate treatments. We will submit as separate studies.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

  NCT06422806· National Cancer Institute (NCI)· Source

• Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

  NCT05333458· National Cancer Institute (NCI)· Source

• Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

  NCT06176989· National Cancer Institute (NCI)· Source

• Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

  NCT05711615· National Cancer Institute (NCI)· Source

• Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

  NCT06222203· National Cancer Institute (NCI)· Source

• Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

  NCT07428993· St. Jude Children's Research Hospital· Source

• Natural History Study of Kaposi Sarcoma

  NCT06375122· National Cancer Institute (NCI)· Source

• Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  NCT02390752· National Cancer Institute (NCI)· Source

• GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors

  NCT07897968· Universität Münster· Source

• Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

  NCT04222413· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 40
• Organoids 10
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 10
• Gene Expression Profiling 99
• Sequence Analysis, RNA 21
• Whole Genome Sequencing 4
• Exome Sequencing 14
• Proteomics 31
• Metabolomics 7
• Mass Spectrometry 5
• Flow Cytometry 52
• Immunohistochemistry 184
• Liquid Biopsy 12
• Circulating Tumor DNA 19
• Xenograft Model Antitumor Assays 152
• Positron-Emission Tomography 19
• Magnetic Resonance Imaging 194
• Machine Learning 28
• Deep Learning 16
• Cohort Studies 30
• Genome-Wide Association Study 2

• Untargeted Metabolite Screening of Ewing Sarcoma Cells and Tissues with Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).

  Methods Mol Biol, Jan 2027

• Metabolomic Analysis of Lytic KSHV Infection: Induced Host Nucleotide Metabolism Is Required for Infectious Virus Production.

  Viruses, Aug 2026

• Omics-Level Approaches to Studying Gammaherpesvirus Infection.

  Pathogens, Jul 2026

• Multi-Omics Profiling of oxylipins and gene expression in pediatric sarcomas identifies metastatic signatures and prognostic models.

  Free Radic Biol Med, May 2026

• Targeting the metabolic fingerprint of amino acids to identify novel metabolic characteristics in osteosarcoma patients undergoing anthracycline treatment.

  Sci Rep, Feb 2026

• Mechanisms of Gualou Beimu Yin in suppressing the development and metastasis of triple-negative breast cancer: an integrated study based on network pharmacology, transcriptomics, and metabolomics.

  J Tradit Chin Med, Feb 2026

• Microbiome and metabolomics analyses of the effect of heat-sensitive moxibustion on allergic rhinitis in rats.

  Front Immunol, Oct 2025

See which targets of this disease your abstract mentions, and go to the people working on them.